Hologic is leveraging advances in artificial intelligence to enhance its point-of-care imaging offerings, positioning its Clarity 3D and Genius AI platforms for broader clinical adoption. With the global point-of-care diagnostics market projected to reach $70.92 billion by 2032, Hologic’s investment in software-defined imaging aims to deliver hospital-grade MRI and CT precision at the bedside. The company’s portable solutions are designed to reduce facility overhead by up to 25% while improving diagnostic throughput, and Hologic has already secured pilot agreements with 12 major health systems ahead of the CMS ACCESS Model launch in July 2026, which will tie Medicare reimbursements to outcome-based performance metrics.

In response to rising underscreening rates—currently leaving an estimated 20% of eligible women without routine Pap plus HPV testing—Hologic has launched Ultimate Defense, a U.S. awareness initiative aimed at boosting annual screening compliance. The campaign will deploy digital outreach across 37 states, partner with 250 community health centers and leverage real-time analytics to identify geographic clusters with screening rates below 65%. Hologic forecasts that a 10% increase in screening adherence could lead to approximately 4,500 additional cervical cancer cases detected at pre-cancer stages annually, reducing treatment costs by an estimated $120 million per year.

Hologic will release its first quarter fiscal 2026 financial results on January 29, 2026 after market close, reflecting performance through December 31, 2025. In light of the pending acquisition by Blackstone and TPG, the company will not host a quarterly conference call or provide forward guidance. Hologic’s board remains confident in the transaction’s strategic rationale, which values the company at approximately $12.6 billion on a debt-free basis, and expects the acquisition to close in the first half of calendar 2026, subject to regulatory approvals.